Ç Â. Ê. åîïìïëïãåßôáé (2)...

Girl Çìïõí ç ðñþôç ðïõ åîïìïëïãÞèçêå ôéò åìðåéñßåò ôçò óå áõôÞ åäþ ôç óåëßäá.

Ôï ìáêñïóêåëÝóôáôï, áãùíéþäåò êåßìåíï ôï åß÷á ãñÜøåé ãýñù óôï 1997. Ôï åß÷á êñáôÞóåé (ôá äñÜìáôá äåí ôá ðåôïýóá ôüôå) êáé ôï äçìïóéåýóá åäþ, üôáí åßäá üôé ìðïñþ.
¹èåëá íá ìïéñáóôþ ôá ìáýñá óõíáéóèÞìáôá êáé ôéò óêïôåéíÝò óêÝøåéò åêåßíïõ ôïõ êáéñïý.
Äåí ìïõ áñêïýóå íá æïýí ìÝóá ìïõ, Þèåëá íôå êáé êáëÜ íá ôïõò äþóù ðåñéóóüôåñï ÷þñï íá æÞóïõí, íá áðëùèïýí ôá ìÝãéóôá!

ÓÞìåñá, 10 ÷ñüíéá ìåôÜ, èÝëù íá îáíáãñÜøù ìåñéêÜ ëüãéá.
¢ëëáîá, êáé èÝëù íá ìïéñáóôþ ìáæß óáò ôá "íÝá"!

Ôçí éäÝá íá ôï êÜíù ôçí ðÞñá áðü êÜðïéá êåßìåíá/åîïìïëïãÞóåéò ðïõ äéÜâáóá óÞìåñá, ìå ôá ïðïßá ôáõôéæüìïõí ðñéí 8-10 ÷ñüíéá êáé ðïõ óÞìåñá äåí ìå åêöñÜæïõí óå ôßðïôá.

ÌÝóá óôá 12 ÷ñüíéá ðïõ åßìáé ïñïèåôéêÞ, Ýêáíá (äüîá ôù Èåþ) êÜðïéåò åíáëëáêôéêÝò åñùôÞóåéò óôïí åáõôü ìïõ:
á) Âñå ìðáò êáé äåí åßìáé êõñßùò ìéá ïñïèåôéêÞ?
Äçë. ó÷åäüí ìüíï Ýíáò éüò ìå ðüäéá? Áò ñßîù áìÝóùò ìéá ìáôéÜ êáé óôéò õðüëïéðåò ðïéüôçôÝò ìïõ, ôá ÷áñßóìáôÜ ìïõ, ôéò ïìïñöéÝò ìïõ.
Áò ôïõò äþóù ôïí ÷þñï êáé ôç óçìáóßá ðïõ ôïõò áîßæåé... êáé ìÝóá óå üëï ôï ôïðßï áð' üóá ìå óõíèÝôïõí êáé ìå áöïñïýí, óå ìéá ãùíßôóá, áò âÜëù êáé ôçí "éäéüôçôá" ôçò ïñïèåôéêÞò ãéá öüíôï.
â) Âñå ìðáò êáé áõôÞ ç áóèÝíåéá Ý÷åé íá "ìïõ ðåß" ðñÜãìáôá ãéá ìÝíá?
ÌÞðùò öÝñíåé ìçíýìáôá ãéá ôçí ðÜñôç ìïõ? ÌÞðùò ìïõ åðéóçìáßíåé ðùò åß÷á ðÜñåé Ýíáí äñüìï ìáêñéÜ áðü ôçí øõ÷ïýëá ìïõ, êé åðåéäÞ ôüôå äåí Üêïõãá êáíÝíáí êáé êõñßùò ôïí åáõôü ìïõ, âñÞêå ç óïöÞ öýóç Ýíáí äõíáìéêü ôñüðï íá ìïõ ôï ðåß?
Ìðáò êáé áõôüò ï åöéÜëôçò áí ôïí ãõñßóù áð' ôçí Üëëç, äéáâÜóù ðùò Ý÷åé êáé ìéá Üëëç ðéèáíÞ ôáõôüôçôá? ÌÞðùò åÜí ôïõ ôï åðéôñÝøù èá ìðïñïýóå íá ëåéôïõñãÞóåé óáí ðéèáíÞ åõêáéñßá?

H ðñáãìáôéêüôçôá åßíáé èÝìá åñìçíåßáò. ¼ðùò ôçí ïíïìÜóåéò, áíôáðïêñßíåôáé. Åìåßò ïñßæïõìå ôçí ôáõôüôçôá ôùí óõìâÜíôùí êáé óôç óõíÝ÷åéá ðñïêáëïýìå êáé ôéò áíÜëïãåò åêâÜóåéò ôïõò, óêÝöôçêá..

Êáé åôÝèç åðåßãïí ôï åñþôçìá: ÊáôáóôñïöÞ Þ åõêáéñßá?

ÐÞñá óôá óïâáñÜ ôéò åñùôÞóåéò ìïõ êáé âÜëèçêá íá äþóù áðáíôÞóåéò.
Ç æùÞ ìïõ Üëëáîå. Ç øõ÷Þ ìïõ Üëëáîå. Ôï Óýìðáí Üëëáîå.
Êáé áõôÞ ç áëëáãÞ ìå ïäÞãçóå óôçí ôåëåõôáßá åñþôçóç:

Âñå ìðáò êáé ç åßäçóç "áíßáôç áóèÝíåéá" äåí åßíáé íôå êáé êáëÜ áëÞèåéá? Áíßáôç áð'Ýîù, áðü ôçí ðëåõñÜ ôïõ ãéáôñïý ï ïðïßïò ôï äçëþíåé. ÌÞðùò êáé åöüóïí ï Üíèñùðïò åßíáé öïñÝáò áõôïúáóçò, èá ìðïñïýóå ìéá ðéèáíÞ ßáóç íá Ýñèåé áðü ìÝóá?

ÕðïèÝôù ðùò èá öÜù êÜðïéåò äéáäéêôõáêÝò ìïýíôæåò ìå ôï êåßìåíü ìïõ. Åßíáé äåêôÝò. Èá óáò óõíéóôïýóá üìùò íá êñáôÞóåôå êáé ìéá ãéá ôïí åáõôü óáò! ¼ðùò Ýêáíá êé åãþ êÜðïôå.

×áéñåôþ ôïõò óõìðáèÝóôáôïõò ößëïõò ðïõ óôçñßæïõí ôï óÜéô áõôü!

Â.Ê




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò